期刊文献+

CEA、CA153、CA125与乳腺癌临床病理因素的关系 被引量:7

Relationship between nipple discharge and serum markers of carcinoembryonic antigen,cancer antigens 125 and cancer antigens 153 levels and clinicopathological factors of breast cancer
下载PDF
导出
摘要 目的研究乳头溢液中癌胚抗原(CEA)、糖类抗原125(CA125)和糖类抗原153(CA153)在乳腺癌中的表达及意义。方法电化学发光法检测日照市人民医院2014年1月至2019年12月间43例乳腺导管癌患者乳头溢液CEA、CA153、CA125水平,与136例乳腺良性病变对照,分析CEA、CA153、CA125水平与乳腺癌临床病理因素的关系。免疫组化Ultra Sensitive;S-P法检测乳腺切除组织ER、PR、Her-2/neu、VEGF和Ki-67。结果乳腺癌患者乳头溢液及血清中CEA、CA153、CA125的含量明显高于良性病变组,差异有统计学意义(P<0.05),乳腺癌组乳头溢液CEA、CA153、CA125水平高于血清水平,差异有统计学意义(P<0.05);乳腺癌观察组不同的组织学分级、淋巴结转移、肿瘤复发、HER-2/neu表达、VEGF和Ki-67指数中患者乳头溢液中CEA、CA153、CA125水平比较,差异有统计学意义(P<0.05)。而不同BMI、ER&PR、患病年龄、肿瘤大小中乳头溢液CEA、CA153、CA125水平比较,差异无统计学意义(P>0.05)。结论乳头溢液CEA、CA153、CA125检测增加了一种潜在的检查途径,和血清中CEA、CA153、CA125肿瘤标志物常规动态检测有助于乳腺癌判断预后,指导监测肿瘤复发转移。 Objective To study the expression and significance of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and carbohydrate antigen 153(CA153)in nipple discharge in breast cancer.Methods The levels of CEA,CA153 and CA125 were detected by Electrochemiluminescence in 43 cases of ductal carcinoma of breast and 136 cases of benign breast lesions between January 2014 and December of-2019 in Rizhao People’s Hospital,and the relationship between nipple discharge CEA,CA153 and CA125 levels and their clinicopathological factors in 43 cases of breast ductal carcinoma of Immunhistochemical Ultra SensitiveTMS-P method was employed to detect the expression of ER,PR,Her-2/neu and Ki-67 in 43 cases of breast invasive carcinoma.Results Our results indicate that the CEA,CA153 and CA125 levels of nipple discharge and serum in breast cancer patients were significantly higher than those in benign lesions,the difference was statistically significant(P<0.05).The levels of CEA,CA153 and CA125 in nipple discharge of breast cancer group were higher than those in serum,the difference was statistically significant(P<0.05).Comparison of the levels of CEA,CA153,and CA125 in the nipple discharge of patients with different histological grades,lymph node metastasis,tumor recurrence,HER-2/neu expression,VEGF and Ki-67 index in the breast cancer observation group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the levels of CEA,CA153,and CA125 in nipple discharge in different BMI,ER&PR,age of disease,and tumor size(P>0.05).Conclusion The detection of CEA,CA153 and CA125 in nipple discharge has increased a potential way of examination,and routine dynamic detection of serum CEA,CA153 and CA125 tumor markers can help breast cancer to predict prognosis and guide the monitoring of tumor recurrence and metastasis.
作者 秦燕 陈英 陈雷 QIN Yan;CHEN Ying;CHEN Lei(Department of laboratory,Rizhao people􀆳s Hospital Affiliated to Jining Medical College,Rizhao,Shandong,China,276826)
出处 《分子诊断与治疗杂志》 2021年第11期1761-1764,1769,共5页 Journal of Molecular Diagnostics and Therapy
基金 济宁医学院教师科研扶持基金(JYFC2018FKJ055)。
关键词 乳腺癌 乳头溢液 血清 癌胚抗原 糖类抗原125 糖类抗原153 Breast cancer Nipple discharge Serum carcinoembryonic antigen Cancer antigens 125 Cancer antigens 153
  • 相关文献

参考文献3

二级参考文献36

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量:29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer [ J]. J Clin Oncol, 2007, 25 (33) :5287-5312.
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Chnical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[ Jl. J Clin Oncol, 2007, 25 ( 1 ) : 118- 145.
  • 5Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth faetor reeeptor 2 testing in breast eaneer: American Society of Clinical Oneology/College of American Pathologists clinical practice guideline update[J]. J Clin Oneol, 2013, 31 (31) :3997-4013.
  • 6Hanna WM, Kwok K. Chromogenic in-situ hybridization:a viable ahernative to fluorescence in-situ hybridization in the HER2 testing algorithm[J]. Mod Pathol, 2006, 19(4) :481-487.
  • 7Park K, Han S, Kim JY, et al. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer [ J ]. J Breast Cancer, 2011, 14(4) :276-282.
  • 8Haines GK 3rd, Wiley E, Susnik B, et al. HER2 in well differentiated breast cancer: is testing necessary? [ J ]. Breast Cancer Res Treat, 2008, 112(3) :551-556.
  • 9Zhu X, Lu Y, Lu H, et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer [J]. Hum Pathol, 2011,42(10) : 1499-1504.
  • 10Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer.9 A fluorescence in situ hybridization and microarray-based CGH analysis[ J]. J Pathol, 2009, 219( 1 ) : 16-24.

共引文献333

同被引文献64

引证文献7

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部